INmune Bio Inc. (NASDAQ: INMB) is -12.76% lower on its value in year-to-date trading and has touched a low of $2.20 and a high of $10.35 in the current 52-week trading range. The INMB stock was last observed hovering at around $5.25 in the last trading session, with the day’s loss setting it -0.19% off its average median price target of $13.00 for the next 12 months. It is also 61.08% off the consensus price target high of $13.00 offered by 3 analysts, but current levels are 27.71% higher than the price target low of $7.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $5.06, the stock is -9.29% and -5.84% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 44241.0 and changing -3.62% at the moment leaves the stock 4.35% off its SMA200. INMB registered -48.10% loss for a year compared to 6-month loss of -12.76%. The firm has a 50-day simple moving average (SMA 50) of $5.61 and a 200-day simple moving average (SMA200) of $4.85.
The stock witnessed a -8.90% gain in the last 1 month and extending the period to 3 months gives it a 57.39%, and is -6.81% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.58% over the week and 8.62% over the month.
Distance from 52-week low is 130.00% and -51.11% from its 52-week high.
INmune Bio Inc. (INMB) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for INmune Bio Inc. (INMB) is a “Buy”. 3 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
INmune Bio Inc. is expected to release its quarterly report on 08/17/2020 and quarterly earnings per share for the current quarter are estimated at -$0.2.The EPS is expected to grow by 41.50% this year.
INmune Bio Inc. (INMB) Top Institutional Holders
17 institutions hold shares in INmune Bio Inc. (INMB), with 6.3M shares held by insiders accounting for 58.23% while institutional investors hold 22.99% of the company’s shares. The shares outstanding are 10.75M, and float is at 4.56M with Short Float at 0.16%. Institutions hold 9.60% of the Float.
The top institutional shareholder in the company is Financial Advocates Investment Management with over 0.25 million shares valued at $0.84 million. The investor’s holdings represent 2.34% of the INMB Shares outstanding. As of Mar 30, 2020, the second largest holder is Deutsche Bank Aktiengesellschaft with 56048.0 shares valued at $0.19 million to account for 0.52% of the shares outstanding. The other top investors are Blackrock Inc. which holds 15752.0 shares representing 0.15% and valued at over $52454.0, while Susquehanna International Group, LLP holds 0.11% of the shares totaling 11443.0 with a market value of $38105.0.
INmune Bio Inc. (INMB) Insider Activity
A total of 1 insider transactions have happened at INmune Bio Inc. (INMB) in the last six months, with sales accounting for 1 and purchases happening 0 times. The most recent transaction is an insider sale by Powers Linda F, the company’s 10% Owner. SEC filings show that Powers Linda F sold 220,000 shares of the company’s common stock on Jan 27 at a price of $4.60 per share for a total of $1.01 million. Following the sale, the insider now owns 0.21 million shares.